Next-gen NMDA

Why Aptinyx aims to modulate rather than block NMDA receptor activity

Naurex Inc. spinout Aptinyx Inc. has a discovery platform and preclinical pipeline of oral small molecule NMDA receptor modulators for CNS disorders that could enhance synaptic plasticity and avoid the adverse events associated with NMDA receptor antagonists.

The programs are expected to have better CNS penetration and oral bioavailability than the more advanced peptides of its parent company, which Allergan plc acquired last year for $560 million up front and undisclosed milestones.

Aptinyx President and CEO Norbert Riedel, who held the

Read the full 821 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers